[ad_1]
The clinical trial was postponed a few days ago due to adverse reactions from a participant in the UK in the final stage of vaccine testing.
In announcing the resumption of the trial, AstraZeneca said on Saturday that the “vaccines” had been suspended in all parts of the trial on September 6 so that international regulators could independently review the safety aspects.
“Safety reviewers have told the UK Medicines Health Regulatory Authority (MHRA) that it is safe to resume trials in the UK.”
The third phase of the AstraZeneca-Oxford vaccine trial has been underway for several weeks after the first and second phase trials were successfully completed. About 30,000 participants from the United States, United Kingdom, Brazil, and South Africa are involved. Testing at this stage often involves thousands of participants and can last for years.
A participant who fell ill in the UK suffered from inflammatory neurological problems in the spine, a disease called transverse myelitis, according to a report by the Reuters news agency.
However, Cambridge-based AstraZeneca declined to comment further on the patient.
The new coronavirus, which began spreading from China late last year and has taken over the world, has already infected more than three and a quarter million people, killing more than 900,000 people.
Kovid-19: How will Bangladesh be vaccinated?
Currently there are about two hundred studies in the world that try to make a vaccine against this virus. Of these, half a dozen potential vaccines have reached the final testing stage.
In addition to the University of Oxford-AstraZeneca, Modernna, Pfizer, Cansino Biological, Synovac Biotech and Synoform are conducting trials of the third phase of their possible vaccine in several countries around the world.
Russia’s Gamaliya Institute has started commercial production with government approval without completing its third phase of the trial.
Before a vaccine is finally approved, a large number of patients must undergo a clinical trial, called a third-stage trial.
If the third stage test is successful, the countries participating in the test grant an emergency authorization. Finally comes the issue of final approval from the World Health Organization.
The World Health Organization says that the Oxford-AstraZeneca vaccine is the most promising. The WHO chief scientist said the discontinuation of the trial should be taken as a “warning message” that there will be ups and downs in the process of developing a vaccine.
[ad_2]
